Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Depreciation & Amortization (CF) (2021 - 2025)

Historic Depreciation & Amortization (CF) for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to $53201.0.

  • InMed Pharmaceuticals' Depreciation & Amortization (CF) changed 0.38% to $53201.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $211460.0, marking a year-over-year decrease of 269.6%. This contributed to the annual value of $212839.0 for FY2025, which is 307.88% down from last year.
  • Per InMed Pharmaceuticals' latest filing, its Depreciation & Amortization (CF) stood at $53201.0 for Q4 2025, which was down 0.38% from $53202.0 recorded in Q3 2025.
  • In the past 5 years, InMed Pharmaceuticals' Depreciation & Amortization (CF) registered a high of $55231.0 during Q4 2023, and its lowest value of $28532.0 during Q3 2021.
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $53202.5 (2024), whereas its average is $51486.0.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first surged by 7190.52% in 2022, then tumbled by 497.0% in 2023.
  • Over the past 5 years, InMed Pharmaceuticals' Depreciation & Amortization (CF) (Quarter) stood at $49797.0 in 2021, then decreased by 1.5% to $49049.0 in 2022, then grew by 12.6% to $55231.0 in 2023, then fell by 3.67% to $53203.0 in 2024, then fell by 0.0% to $53201.0 in 2025.
  • Its last three reported values are $53201.0 in Q4 2025, $53202.0 for Q3 2025, and $52752.0 during Q2 2025.